Medeon Biodesign, Inc. (6499) AI Stock Analysis

Medeon Biodesign, Inc.

(TPEx:6499)

Select Model

Rating:33Underperform

Price Target:TWD 65.00▼(-11.92% Downside)

Action:initiatedcoverage

Date:11/09/26

The score is driven primarily by weak financial performance: heavy operating losses, a net margin near -159%, deteriorating gross margins and a cash burn of roughly NT$646 million per year that leaves limited runway and raises the prospect of equity dilution. A nearly debt-free balance sheet and two consecutive years of narrowing losses and improving burn provide some resilience, but they do not offset the fundamental profitability gap. Technicals add further pressure, with the price below all key moving averages and negative MACD, though oversold readings hint at possible near-term stabilization. Valuation offers no support given negative earnings and no dividend. The investment case rests entirely on revenue scaling with much better margins before capital is exhausted, making this a speculative holding.

Positive Factors

Revenue ExpansionMeaningful revenue expansion in the last two years indicates improving commercial traction and a broader base for future operating leverage. If this growth persists, it can strengthen market reach and create a foundation for better earnings, although profitability has not yet followed.

Negative Factors

Persistent Operating LossesLarge continuing operating and net losses show that revenue growth and improved gross margin have not yet translated into a sustainable business model. Without meaningful cost-structure improvement, ongoing losses can consume resources, limit reinvestment, and prolong the path to self-funded growth.

Medeon Biodesign, Inc. (6499) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 6.92B
Dividend Yield: ―
Average Volume (3M): 373.34K
Price to Earnings (P/E): -16.4
Beta (1Y): 0.50
Revenue Growth: 69.62%
EPS Growth: 59.41%
Country: TW
Employees: 1,496
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Medeon Biodesign, Inc. Business Overview & Revenue Model

Company Description

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular clo...

Medeon Biodesign, Inc. Financial Statement Overview

Summary

Medeon Biodesign remains a development-stage, deeply loss-making business. Revenue grew roughly 43% to NT$419 million, but the net loss of NT$668 million implies a net margin near -159%, and gross margin compressed sharply from 28.5% to 14.0%, signaling pricing or cost pressure as volumes scale. Cash flow is the biggest risk: operations consumed NT$629 million and free cash flow was negative NT$646 million, leaving only a couple of years of runway against NT$1.48 billion of equity and raising realistic dilution risk. The main offset is a clean, nearly debt-free balance sheet (debt-to-equity of 0.08, equity funding 83% of assets), though equity has eroded from NT$4.13 billion in 2021 as accumulated losses mount. Losses and burn have narrowed for two consecutive years, which is encouraging but far from breakeven.

Income Statement

23Negative

Balance Sheet

46Neutral

Cash Flow

16Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	428.06M	419.43M	292.81M	196.26M	298.32M	68.96M
Gross Profit	39.23M	58.83M	83.41M	-65.20M	186.81M	28.63M
EBITDA	-540.29M	-615.15M	-754.42M	-1.14B	-370.10M	-453.87M
Net Income	-575.91M	-668.06M	-805.51M	-1.20B	-433.76M	2.08B
Balance Sheet
Total Assets	1.55B	1.78B	1.88B	2.75B	4.04B	4.36B
Cash, Cash Equivalents and Short-Term Investments	959.51M	1.22B	1.21B	2.14B	1.55B	2.35B
Total Debt	151.49M	113.05M	168.40M	186.74M	198.91M	30.24M
Total Liabilities	282.14M	243.03M	341.84M	375.65M	376.48M	176.00M
Stockholders Equity	1.23B	1.48B	1.52B	2.32B	3.60B	4.13B
Cash Flow
Free Cash Flow	-520.83M	-645.56M	-907.44M	-810.36M	-602.06M	-302.39M
Operating Cash Flow	-511.73M	-629.09M	-832.66M	-755.08M	-461.34M	-293.38M
Investing Cash Flow	-118.74M	272.56M	135.21M	1.60B	263.44M	-90.64M
Financing Cash Flow	374.49M	373.88M	-46.68M	-90.57M	-101.16M	-3.90M

Medeon Biodesign, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6499 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4107	78Outperform	TWD 7.35B	12.29	―	5.12%	10.16%	17.15%
TW:4129	68Neutral	TWD 7.01B	12.73	―	6.19%	18.91%	10.75%
TW:4163	59Neutral	TWD 6.41B	20.66	―	2.78%	4.16%	40.82%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6499	33Underperform	TWD 7.33B	-16.44	―	―	69.62%	59.41%

* General Sector Average

Performance Comparison

TW:6499 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6499	Medeon Biodesign, Inc.	73.80	-23.20	-23.92%
TW:4107	Bioteque Corporation	107.50	-14.13	-11.62%
TW:4129	United Orthopedic Corporation	72.70	-42.36	-36.82%
TW:4163	Intai Technology Corp.	126.00	29.44	30.48%
TW:6891	Locus Cell Co., Ltd.	37.30	7.55	25.38%
TW:6907	Artery Technology Corporation	123.50	74.84	153.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Medeon Biodesign, Inc. AI Stock Analysis